This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

45/100

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

The 4R-like pattern was more prevalent and more strongly expressed (84.3%, mean score, 2.0 ± 1.1) in patients with a consensus diagnosis of PSP/CBD (joint diagnostic group of clinically likely 4R tauopathies) than in all other groups (11.6%, 0.26 ± 0.75, P < 0.0001). An AD-like pattern was present in all patients with a consensus diagnosis of AD (100%, 2.5 ± 0.9) and at high frequency, albeit with lower magnitude, in all other patient groups (67.4%, 1.2 ± 1.1, P < 0.01). ROC analysis for the 4R-like pattern (PSP/CBD vs. all other patients) yielded an area under the ROC curve (AUC) of 0.87 (sensitivity, 84.3%; specificity, 88.4%). The diagnostic performance of [18F]florzolotau PET did not change when also considering the AD-like pattern (AUC, 0.88; logistic regression, factor AD-like pattern; P = 0.53) or excluding all cases with AD (AUC, 0.86). The presence of corticobasal syndrome in patients with 4R-like binding was strongly associated with preferentially cortical binding (AUC, 0.89). Based on a real-world population of patients with parkinsonism, we demonstrate that simple visual evaluation of [18F]florzolotau PET by an a priori–defined 4R-like binding pattern allows highly accurate identification of patients with a consensus diagnosis of PSP/CBD. Thus, [18F]florzolotau PET is a promising biomarker for differential diagnosis of neurodegenerative parkinsonian syndromes.

Key findings

The 4R-like pattern was more prevalent and more strongly expressed (84.3%, mean score, 2.0 ± 1.1) in patients with a consensus diagnosis of PSP/CBD (joint diagnostic group of clinically likely 4R tauopathies) than in all other groups (11.6%, 0.26 ± 0.75, P < 0.0001).
An AD-like pattern was present in all patients with a consensus diagnosis of AD (100%, 2.5 ± 0.9) and at high frequency, albeit with lower magnitude, in all other patient groups (67.4%, 1.2 ± 1.1, P < 0.01).
ROC analysis for the 4R-like pattern (PSP/CBD vs. all other patients) yielded an area under the ROC curve (AUC) of 0.87 (sensitivity, 84.3%; specificity, 88.4%).
The diagnostic performance of [18F]florzolotau PET did not change when also considering the AD-like pattern (AUC, 0.88; logistic regression, factor AD-like pattern; P = 0.53) or excluding all cases with AD (AUC, 0.86).
The presence of corticobasal syndrome in patients with 4R-like binding was strongly associated with preferentially cortical binding (AUC, 0.89).

Why it matters

In patients with parkinsonism, a 4R-like binding pattern on [18F]florzolotau PET identified those with a consensus diagnosis of PSP/CBD with an area under the ROC curve of 0.87. The authors call it a promising biomarker for differential diagnosis, not a treatment or cure.

Study details

Effect size84.3%; 11.6%; 67.4%
Evidence strengthModerate

How this study scored 45/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of Nuclear Medicine)
Journal's citation record	2 / 4	Journal of Nuclear Medicine: journal h-index 230 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 9 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	3.0 citations a year over 3 year(s) since 2025
Impact for its field and year	3 / 6	Cited 5.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Philipp Tobias Meyer: h-index 52 (OpenAlex, whole career)
Institution's track record	1 / 3	University of Freiburg: institution h-index 1,068 (OpenAlex)
Multi-centre collaboration	1 / 3	OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40246540)
Free to read	2 / 2	Free to read
Total	45 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Brumberg, J., Schröter, N., Blazhenets, G., Omrane, M. A., Volz, C. H., Weiller, C., et al. (2025). [18F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268956

Vancouver

Brumberg J, Schröter N, Blazhenets G, Omrane MA, Volz CH, Weiller C, et al. [18F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268956. PMID: 40246540.

BibTeX

@article{brumberg2025-40246540,
  author  = {Brumberg, Joachim and Schröter, Nils and Blazhenets, Ganna and Omrane, Mohamed Aymen and Volz, Christian H. and Weiller, Cornelius and Rijntjes, Michel and Frings, Lars and others},
  title   = {{[18F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies}},
  journal = {Journal of Nuclear Medicine},
  year    = {2025},
  doi     = {10.2967/jnumed.124.268956},
  pmid    = {40246540},
  url     = {https://doi.org/10.2967/jnumed.124.268956}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Disease mechanisms

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →